HOUSE_OVERSIGHT_024046.jpg
2.41 MB
Extraction Summary
3
People
8
Organizations
0
Locations
2
Events
2
Relationships
2
Quotes
Document Information
Type:
Investment memorandum / private placement memorandum
File Size:
2.41 MB
Summary
This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.
People (3)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Investment Managers |
Managers of NLV-II and NLV-III funds, describing their strategy.
|
| NLV team member | Board Member |
Joined the board of Array Pharmaceuticals.
|
| NLV team member | Board Member |
Initially joined the board of Intercept Pharmaceuticals.
|
Organizations (8)
Relationships (2)
led a structured follow-on investment
anchored company’s IPO
Key Quotes (2)
"The Fund Managers believe that NLV-III will be invested in a market with attractive conditions for investment in the biopharmaceutical sector."Source
HOUSE_OVERSIGHT_024046.jpg
Quote #1
"Where possible, the Fund will look to invest in companies with product programs that are guided by validated biomarkers that can enable highly specific patient selection and provide an objective measurement of drug effect."Source
HOUSE_OVERSIGHT_024046.jpg
Quote #2
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document